The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to eMarketer. Obesity drugs have also started showing up in emp ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...
Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
Zacks Investment Research on MSN1d
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & MoreBayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
Hims & Hers Health ( HIMS -12.56%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback